Viracta Therapeutics Inc SEC Filings

VIRX OTC

Welcome to our dedicated page for Viracta Therapeutics SEC filings (Ticker: VIRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Parsing a biotech filing packed with virology terms and clinical trial minutiae can drain hours. Viracta Therapeutics’ disclosures are especially dense: every 10-K details cash runway for Nana-val, every 8-K flags trial milestones, and Form 4s hint at management’s confidence in this EBV-focused pipeline. Stock Titan surfaces what matters the moment it hits EDGAR.

Our AI reads each page so you don’t have to. It highlights R&D expense shifts in the Viracta Therapeutics quarterly earnings report 10-Q filing, translates complex risk factors in the Viracta Therapeutics annual report 10-K simplified, and delivers real-time alerts the instant Viracta Therapeutics Form 4 insider transactions real-time are posted. Need to understand material events? The platform pairs every notice with plain-English context—think Viracta Therapeutics 8-K material events explained in minutes, not days.

Below is a quick guide to the questions investors ask—and the filings that answer them:

Viracta Therapeutics insider trading Form 4 transactions – monitor executive buys and sells.
Viracta Therapeutics earnings report filing analysis – track trial spending versus cash reserves.
Viracta Therapeutics proxy statement executive compensation – review incentives tied to Nana-val milestones.
understanding Viracta Therapeutics SEC documents with AI – our summaries decode scientific jargon.

Whether you’re comparing quarter-over-quarter burn rates, following Viracta Therapeutics executive stock transactions Form 4, or simply looking for Viracta Therapeutics SEC filings explained simply, Stock Titan delivers complete coverage, real-time updates, and AI-powered clarity that turns technical disclosures into actionable insight.

07/10/2025 10:36 AM

Filing

[25-NSE] VIRACTA THERAPEUTICS INC SEC Filing

Rhea-AI Summary

Viracta Therapeutics, Inc. (Nasdaq: VIRX) has been slated for removal from the Nasdaq Stock Market. Nasdaq filed a Form 25 on 10 July 2025 to strike the company’s common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. The exchange certifies that it meets all requirements of 17 CFR 240.12d2-2(b) for delisting and that the issuer and exchange have complied with applicable rules. The notice was signed by Hearings Advisor Aravind Menon. No financial results, earnings data, or additional corporate context are provided in this filing.

The delisting will end Nasdaq trading in VIRX shares and terminate their Section 12(b) registration. Investors should expect the shares to trade on an over-the-counter venue or another qualified market once the Form 25 becomes effective.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Viracta Therapeutics (VIRX)?

The current stock price of Viracta Therapeutics (VIRX) is $0.00978 as of July 16, 2025.

What is the market cap of Viracta Therapeutics (VIRX)?

The market cap of Viracta Therapeutics (VIRX) is approximately 6.0M.

What is the core focus of Viracta Therapeutics?

Viracta Therapeutics focuses on developing precision oncology therapies, specifically viral gene activation treatments for virus-associated cancers, including those linked to Epstein-Barr virus (EBV).

What is Nana-val and how does it work?

Nana-val is an all-oral combination regimen that pairs the investigational drug nanatinostat with antiviral valganciclovir, designed to induce the expression of viral genes in cancer cells and combat EBV-positive malignancies.

Which patient populations does Viracta target?

The company primarily targets patients with relapsed or refractory EBV-positive cancers, such as peripheral T-cell lymphoma, while also exploring other virus-associated oncological indications.

How does Viracta differentiate itself in the oncology sector?

Viracta differentiates itself through its unique approach of viral gene activation therapy, which offers a targeted treatment for viruses implicated in oncogenesis, setting it apart from more traditional cancer therapies.

What are the strategic operational steps taken by Viracta?

Viracta has implemented workforce and board restructuring to optimize resources and streamline operations, ensuring focused execution of its clinical development programs.

How does the company engage with regulatory agencies?

The company actively consults with regulatory bodies, such as the FDA, to receive guidance on its clinical trial designs and regulatory path, which supports its structured progression through clinical phases.

What industry-specific terms are integral to Viracta's approach?

Key industry terms include precision oncology, viral gene activation, EBV-associated cancers, and epigenetic modulation, all of which underpin the company’s innovative therapeutic strategy.

How is Viracta positioned within the competitive landscape?

Viracta occupies a unique niche by focusing on virus-associated cancers with an innovative therapeutic approach, positioning it as a specialized player in the broader oncology and biopharmaceutical sectors.